Loading
Life sciences · Journal article
Asian Journal of Chemistry · September 5, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of bis-indole derivative chemistry and preclinical pharmacology across multiple therapeutic areas. Most candidates remain at the preclinical or experimental stage, with identified barriers including poor aqueous solubility, limited bioavailability, metabolic instability, off-target interactions, and potential toxicity. The review raises research questions and identifies future directions rather than providing evidence of clinical efficacy.
Journal article. Preclinical and experimental bis-indole derivatives; no human subjects studied.
Bis-indole derivatives investigated across cancer, infectious diseases, inflammation, neurological and metabolic disorders Reported mechanisms include modulation of protein kinases, topoisomerases, microtubule dynamics, inflammatory signalling, oxidative stress and drug-efflux pathways Most bis-indole candidates remain at the preclinical or experimental stage
Significant barriers identified: poor aqueous solubility, limited bioavailability, metabolic instability, off-target interactions and potential toxicity
This review does not provide evidence to guide clinical practice. It describes the current landscape of bis-indole research and identifies unmet needs and barriers to development; clinicians should not use this to inform patient care decisions.
This is a narrative review of bis-indole chemistry and preclinical biology that raises questions about therapeutic potential rather than reporting empirical evidence from clinical or controlled trials.
This review does not provide evidence to guide clinical practice. It describes the current landscape of bis-indole research and identifies unmet needs and barriers to development; clinicians should not use this to inform patient care decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Bis-indole derivatives represent an important class of indole-based compounds with substantial structural diversity and broad pharmacological potential. The presence of two indole units, connected through direct bonds or diverse linkers, provides opportunities to modulate molecular conformation, target interactions and biological activity through systematic structural modification. This review provides a critical overview of recent advances in bis-indole chemistry, with emphasis on synthetic methodologies, biological activities, structure-activity relationships and emerging therapeutic applications. Conventional synthetic approaches, such as acid-catalyzed condensation, oxidative coupling and stepwise functionalization, are discussed together with more recent developments in transition-metal catalysis, multicomponent reactions, microwave-assisted synthesis, photoredox and electrochemical transformations and sustainable catalytic systems. These approaches have expanded the accessible structural diversity of bis-indoles and improved reaction efficiency, selectivity and, in several cases, sustainability. Biologically, bis-indole derivatives have been investigated across diverse therapeutic areas, including cancer, infectious diseases, inflammation, neurological and metabolic disorders. Reported mechanisms include modulation of protein kinases, topoisomerases, microtubule dynamics, inflammatory signalling, oxidative stress and drug-efflux pathways, although the strength of mechanistic evidence varies among individual compounds. Beyond conventional pharmacological applications, bis-indole frameworks have also been explored in photodynamic therapy, molecular imaging, drug-resistance modulation and drug-delivery systems. Despite extensive research, most bis-indole candidates remain at the preclinical or experimental stage. Poor aqueous solubility, limited bioavailability, metabolic instability, off-target interactions and potential toxicity remain significant barriers to clinical development. In addition, regioselective and stereoselective synthesis, scalability and reproducibility require further improvement. Future progress will depend on establishing clearer relationships among molecular structure, target engagement, biological activity, pharmacokinetic behaviour and toxicity. Integration of sustainable synthesis, medicinal chemistry, structural biology, computational modelling and data-driven approaches, supported by standardized biological evaluation, may facilitate the identification of better-characterized candidates. Such efforts could help translate the broad chemical and biological potential of bis-indoles into therapeutically relevant applications.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.